Compare MOV & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOV | CYBN |
|---|---|---|
| Founded | 1961 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.7M | 416.1M |
| IPO Year | 1993 | N/A |
| Metric | MOV | CYBN |
|---|---|---|
| Price | $22.37 | $8.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $31.50 | ★ $74.50 |
| AVG Volume (30 Days) | 144.8K | ★ 916.5K |
| Earning Date | 11-25-2025 | 02-10-2026 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | ★ 27.72 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $661,205,000.00 | N/A |
| Revenue This Year | $2.10 | N/A |
| Revenue Next Year | $0.24 | N/A |
| P/E Ratio | $22.48 | ★ N/A |
| Revenue Growth | ★ 2.78 | N/A |
| 52 Week Low | $12.85 | $4.81 |
| 52 Week High | $22.36 | $10.73 |
| Indicator | MOV | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 65.82 | 68.97 |
| Support Level | $20.74 | $7.85 |
| Resistance Level | $21.45 | $9.12 |
| Average True Range (ATR) | 0.58 | 0.51 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 89.55 | 68.59 |
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.